JP2012514601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514601A5 JP2012514601A5 JP2011544638A JP2011544638A JP2012514601A5 JP 2012514601 A5 JP2012514601 A5 JP 2012514601A5 JP 2011544638 A JP2011544638 A JP 2011544638A JP 2011544638 A JP2011544638 A JP 2011544638A JP 2012514601 A5 JP2012514601 A5 JP 2012514601A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimido
- diazepine
- methyl
- methoxy
- phenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carbocycle Chemical group 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 125000003118 aryl group Chemical group 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 150000002148 esters Chemical class 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- PKVNVXXWANAAFP-UHFFFAOYSA-N 1,7-dihydro-1,4-diazepin-6-one Chemical compound O=C1CNC=CN=C1 PKVNVXXWANAAFP-UHFFFAOYSA-N 0.000 claims 3
- AZQDLBJZOAHSAZ-UHFFFAOYSA-N 1,7-dihydrodiazepin-6-one Chemical compound O=C1CNN=CC=C1 AZQDLBJZOAHSAZ-UHFFFAOYSA-N 0.000 claims 3
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 claims 3
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- BUBBBFSEOYHUQA-UHFFFAOYSA-N 2,5-dihydrooxazepin-6-one Chemical compound O1NC=CCC(C1)=O BUBBBFSEOYHUQA-UHFFFAOYSA-N 0.000 claims 2
- VVPYTOVXFOGRIN-UHFFFAOYSA-N 2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N(CC1)CCC1N1CCN(C)CC1 VVPYTOVXFOGRIN-UHFFFAOYSA-N 0.000 claims 2
- LZNDHLKMOBVBFV-UHFFFAOYSA-N 4-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 LZNDHLKMOBVBFV-UHFFFAOYSA-N 0.000 claims 2
- 101100268648 Mus musculus Abl1 gene Proteins 0.000 claims 2
- QAPAJIZPZGWAND-UHFFFAOYSA-N XMD8-92 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 QAPAJIZPZGWAND-UHFFFAOYSA-N 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- NFNBVXVXMQZSGB-UHFFFAOYSA-N 11-cyclopentyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1=CC=CC=C1N2C1CCCC1 NFNBVXVXMQZSGB-UHFFFAOYSA-N 0.000 claims 1
- JGVXSQJYBQAPAE-UHFFFAOYSA-N 11-ethyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(CC)C3=CC=CC=C3C(=O)N(C)C2=CN=C1NC(C(=C1)OC)=CC=C1N1CCN(C)CC1 JGVXSQJYBQAPAE-UHFFFAOYSA-N 0.000 claims 1
- ASAFHHFHFUCJHM-UHFFFAOYSA-N 11-methyl-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)NC3=CN=2)C(OC(C)C)=CC=1N1CCN(C)CC1 ASAFHHFHFUCJHM-UHFFFAOYSA-N 0.000 claims 1
- LHBAORXBTTWPDF-UHFFFAOYSA-N 2-[2-ethoxy-4-(4-hydroxypiperidin-1-yl)anilino]-5-methyl-9-phenyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CCOC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1=CC=CC=C1 LHBAORXBTTWPDF-UHFFFAOYSA-N 0.000 claims 1
- DDTPGANIPBKTNU-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methyl-1-piperazinyl)anilino]-5,11-dimethyl-6-pyrimido[4,5-b][1,4]benzodiazepinone Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 DDTPGANIPBKTNU-UHFFFAOYSA-N 0.000 claims 1
- KXCGZEPWZFXPSC-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-4,11-dimethyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)NC3=C(C)N=2)C(OC)=CC=1N1CCN(C)CC1 KXCGZEPWZFXPSC-UHFFFAOYSA-N 0.000 claims 1
- OXTSNXXVWGKOMB-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-4,5,11-trimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=C(C)N=2)C(OC)=CC=1N1CCN(C)CC1 OXTSNXXVWGKOMB-UHFFFAOYSA-N 0.000 claims 1
- WBPCKVJWZORAAO-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dihydropyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3NC4=CC=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 WBPCKVJWZORAAO-UHFFFAOYSA-N 0.000 claims 1
- NYHLZQOMTUZDHV-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,8,11-trimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(C)C=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 NYHLZQOMTUZDHV-UHFFFAOYSA-N 0.000 claims 1
- YYTFTZONXCQXLW-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methyl-11-propan-2-ylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C(C)C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 YYTFTZONXCQXLW-UHFFFAOYSA-N 0.000 claims 1
- GTCWEOILNAZCDT-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methyl-11h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3NC4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 GTCWEOILNAZCDT-UHFFFAOYSA-N 0.000 claims 1
- NTRCYAXJQIZACU-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrimido[4,5-b][1,4]benzothiazepin-6-one Chemical compound C=1C=C(NC=2N=C3SC4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 NTRCYAXJQIZACU-UHFFFAOYSA-N 0.000 claims 1
- OGHDOVJGVKNHRQ-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5h-pyrimido[4,5-b][1,4]benzothiazepin-6-one Chemical compound C=1C=C(NC=2N=C3SC4=CC=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 OGHDOVJGVKNHRQ-UHFFFAOYSA-N 0.000 claims 1
- KBULREVCYROFNX-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8,11-dimethyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(C)C=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 KBULREVCYROFNX-UHFFFAOYSA-N 0.000 claims 1
- HQHQZEUABJAAMZ-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-9-phenyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CCN2C1=CC=CC=C1 HQHQZEUABJAAMZ-UHFFFAOYSA-N 0.000 claims 1
- UDMGPKXTQNCFIO-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazine-1-carbonyl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N1CCN(C)CC1 UDMGPKXTQNCFIO-UHFFFAOYSA-N 0.000 claims 1
- XYKSVLLNDQRZDK-UHFFFAOYSA-N 2-[2-methoxy-5-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C1=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=C1C(=O)N(CC1)CCC1N1CCN(C)CC1 XYKSVLLNDQRZDK-UHFFFAOYSA-N 0.000 claims 1
- YSFFGUHMDPYPAW-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCC(O)CC1 YSFFGUHMDPYPAW-UHFFFAOYSA-N 0.000 claims 1
- NPRYKZQCTXZUKH-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC(C)C)=CC=1N1CCC(O)CC1 NPRYKZQCTXZUKH-UHFFFAOYSA-N 0.000 claims 1
- NGXGUOYOCNOKJO-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-5-methyl-9-phenyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CC(C)OC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1=CC=CC=C1 NGXGUOYOCNOKJO-UHFFFAOYSA-N 0.000 claims 1
- RUSIEYRQPZZDCO-UHFFFAOYSA-N 2-[4-[4-(2-hydroxyethyl)piperazine-1-carbonyl]-2-methoxyanilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N1CCN(CCO)CC1 RUSIEYRQPZZDCO-UHFFFAOYSA-N 0.000 claims 1
- YMOOMBLIPWGVAG-UHFFFAOYSA-N 2-[[5-(4-hydroxypiperidin-1-yl)pyridin-2-yl]amino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(C)C3=CC=CC=C3C(=O)N(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 YMOOMBLIPWGVAG-UHFFFAOYSA-N 0.000 claims 1
- FMJVGPKPZYQCHQ-UHFFFAOYSA-N 2-cyclopentyl-13-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-9-methyl-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-8-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 FMJVGPKPZYQCHQ-UHFFFAOYSA-N 0.000 claims 1
- FWCFYOYWYWAYRZ-UHFFFAOYSA-N 2-cyclopentyl-13-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-9-methyl-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-8-one Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 FWCFYOYWYWAYRZ-UHFFFAOYSA-N 0.000 claims 1
- YXQSBQOOYOWCJL-UHFFFAOYSA-N 3-[(5,11-dimethyl-6-oxopyrimido[4,5-b][1,4]benzodiazepin-2-yl)amino]-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1NC1=NC=C(N(C)C(=O)C=2C(=CC=CC=2)N2C)C2=N1 YXQSBQOOYOWCJL-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- XBWVKVCSCJYKTP-UHFFFAOYSA-N 4-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-3-methoxy-N-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 XBWVKVCSCJYKTP-UHFFFAOYSA-N 0.000 claims 1
- REFAILJSNNDVNL-UHFFFAOYSA-N 4-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 REFAILJSNNDVNL-UHFFFAOYSA-N 0.000 claims 1
- WSLOEKAMNQLCHA-UHFFFAOYSA-N 4-[(5,11-dimethyl-6-oxopyrimido[4,5-b][1,4]benzodiazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C=2C(=CC=CC=2)N2C)C2=N1 WSLOEKAMNQLCHA-UHFFFAOYSA-N 0.000 claims 1
- JFRNFMQDZRWAQB-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 JFRNFMQDZRWAQB-UHFFFAOYSA-N 0.000 claims 1
- YPTCBEGMGVTHLV-UHFFFAOYSA-N 4-[(9-cyclopentyl-6-oxo-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CCN2C1CCCC1 YPTCBEGMGVTHLV-UHFFFAOYSA-N 0.000 claims 1
- 102100022681 40S ribosomal protein S27 Human genes 0.000 claims 1
- HGOKWKGWPGOSCA-UHFFFAOYSA-N 5-ethyl-2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]-11-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(C)C3=CC=CC=C3C(=O)N(CC)C2=CN=C1NC(C(=C1)OC)=CC=C1N1CCC(O)CC1 HGOKWKGWPGOSCA-UHFFFAOYSA-N 0.000 claims 1
- UJDYKWMGSWQRHC-UHFFFAOYSA-N 5-ethyl-2-[[5-(4-hydroxypiperidin-1-yl)pyridin-2-yl]amino]-11-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(C)C3=CC=CC=C3C(=O)N(CC)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 UJDYKWMGSWQRHC-UHFFFAOYSA-N 0.000 claims 1
- NGLWEPBNFIVDCQ-UHFFFAOYSA-N 6-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-N-methylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 NGLWEPBNFIVDCQ-UHFFFAOYSA-N 0.000 claims 1
- MUKRTRBUCKPVNQ-UHFFFAOYSA-N 8-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-11-methyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(Cl)C=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 MUKRTRBUCKPVNQ-UHFFFAOYSA-N 0.000 claims 1
- VHGSQSKYNALGRI-UHFFFAOYSA-N 8-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(Cl)C=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 VHGSQSKYNALGRI-UHFFFAOYSA-N 0.000 claims 1
- RHSOYHKODVPGTH-UHFFFAOYSA-N 9-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC(Cl)=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 RHSOYHKODVPGTH-UHFFFAOYSA-N 0.000 claims 1
- ACHCMXBSPWFSTG-UHFFFAOYSA-N 9-cyclopentyl-2-[2-ethoxy-4-(4-hydroxypiperidin-1-yl)anilino]-5-ethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CCOC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(CC)C(=O)CCN2C1CCCC1 ACHCMXBSPWFSTG-UHFFFAOYSA-N 0.000 claims 1
- JPPAAAXZOZVWJV-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,8-dimethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CC(C)N2C1CCCC1 JPPAAAXZOZVWJV-UHFFFAOYSA-N 0.000 claims 1
- OJWZTBKXQCIUGC-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8-methyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CC(C)N2C1CCCC1 OJWZTBKXQCIUGC-UHFFFAOYSA-N 0.000 claims 1
- DIKJXQJRGJEYBE-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5,8-dimethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CC(C)N2C1CCCC1 DIKJXQJRGJEYBE-UHFFFAOYSA-N 0.000 claims 1
- DDNLIQKMQDMWSC-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-8-methyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CC(C)N2C1CCCC1 DDNLIQKMQDMWSC-UHFFFAOYSA-N 0.000 claims 1
- FNISJKXTBDDMGF-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4-hydroxy-4-methylpiperidin-1-yl)-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(C)(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 FNISJKXTBDDMGF-UHFFFAOYSA-N 0.000 claims 1
- KBILTEUAXWLXKP-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 KBILTEUAXWLXKP-UHFFFAOYSA-N 0.000 claims 1
- LTQRUCOWRVPXHK-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CC(C)OC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 LTQRUCOWRVPXHK-UHFFFAOYSA-N 0.000 claims 1
- RSYDNACOROMVHV-UHFFFAOYSA-N 9-cyclopentyl-2-[4-[2-hydroxyethyl(methyl)amino]-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N(C)CCO)=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 RSYDNACOROMVHV-UHFFFAOYSA-N 0.000 claims 1
- PPPDATIUXAGJGR-UHFFFAOYSA-N 9-cyclopentyl-2-[4-[3-hydroxypropyl(methyl)amino]-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N(C)CCCO)=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 PPPDATIUXAGJGR-UHFFFAOYSA-N 0.000 claims 1
- POBSLBATAWVCHO-UHFFFAOYSA-N 9-cyclopentyl-2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(CCO)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 POBSLBATAWVCHO-UHFFFAOYSA-N 0.000 claims 1
- OKQDXMMMFVXHAW-UHFFFAOYSA-N 9-cyclopentyl-5-ethyl-2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CCC(=O)N(CC)C2=CN=C1NC(C(=C1)OC(C)C)=CC=C1N1CCC(O)CC1 OKQDXMMMFVXHAW-UHFFFAOYSA-N 0.000 claims 1
- YODJTHMUSBWPPF-UHFFFAOYSA-N 9-fluoro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-11-methyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC(F)=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 YODJTHMUSBWPPF-UHFFFAOYSA-N 0.000 claims 1
- VOMMOJXYDRSJDB-UHFFFAOYSA-N 9-fluoro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC(F)=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 VOMMOJXYDRSJDB-UHFFFAOYSA-N 0.000 claims 1
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims 1
- MJWFWWQYJUYLME-UHFFFAOYSA-N C12CCCC2C(=O)N(C)C2=CN=C(NCCO)N=C2N1C1CCCC1 Chemical compound C12CCCC2C(=O)N(C)C2=CN=C(NCCO)N=C2N1C1CCCC1 MJWFWWQYJUYLME-UHFFFAOYSA-N 0.000 claims 1
- WRHUGGCQUAYYDQ-UHFFFAOYSA-N C1CN(C)CCC1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 Chemical compound C1CN(C)CCC1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 WRHUGGCQUAYYDQ-UHFFFAOYSA-N 0.000 claims 1
- OCLDKOPBXYVCHQ-UHFFFAOYSA-N C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 OCLDKOPBXYVCHQ-UHFFFAOYSA-N 0.000 claims 1
- YJOJNCMEFOKLDY-UHFFFAOYSA-N C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 YJOJNCMEFOKLDY-UHFFFAOYSA-N 0.000 claims 1
- JNYFWESQXFKIGG-UHFFFAOYSA-N C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 JNYFWESQXFKIGG-UHFFFAOYSA-N 0.000 claims 1
- IAMXXMOPUGAJEU-UHFFFAOYSA-N C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 Chemical compound C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 IAMXXMOPUGAJEU-UHFFFAOYSA-N 0.000 claims 1
- RJWOSNXCRBEXEQ-UHFFFAOYSA-N C=1C=C(NC=2N=C3N4CCCC4CC(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N4CCCC4CC(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 RJWOSNXCRBEXEQ-UHFFFAOYSA-N 0.000 claims 1
- LFZHXUKTGCSQNI-UHFFFAOYSA-N CC(C)OC1=CC(C(=O)N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 Chemical compound CC(C)OC1=CC(C(=O)N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 LFZHXUKTGCSQNI-UHFFFAOYSA-N 0.000 claims 1
- WSGUAIUSADDSHS-UHFFFAOYSA-N COC1=CC(C(=O)N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 Chemical compound COC1=CC(C(=O)N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 WSGUAIUSADDSHS-UHFFFAOYSA-N 0.000 claims 1
- JGDSAHBYNOMOSG-UHFFFAOYSA-N COC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 Chemical compound COC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 JGDSAHBYNOMOSG-UHFFFAOYSA-N 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 claims 1
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 101001018978 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims 1
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 claims 1
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 claims 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 1
- 101001051723 Homo sapiens Ribosomal protein S6 kinase alpha-6 Proteins 0.000 claims 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 claims 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 1
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 claims 1
- 101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 claims 1
- 101000885321 Homo sapiens Serine/threonine-protein kinase DCLK1 Proteins 0.000 claims 1
- 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 claims 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 claims 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 claims 1
- 101000838596 Homo sapiens Serine/threonine-protein kinase TAO3 Proteins 0.000 claims 1
- 101000607332 Homo sapiens Serine/threonine-protein kinase ULK2 Proteins 0.000 claims 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims 1
- IWMCPJZTADUIFX-UHFFFAOYSA-N LRRK2-IN-1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N(CC1)CCC1N1CCN(C)CC1 IWMCPJZTADUIFX-UHFFFAOYSA-N 0.000 claims 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims 1
- WELBJLUKWAJOQV-UHFFFAOYSA-N Mps1-IN-2 Chemical compound CCOC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 WELBJLUKWAJOQV-UHFFFAOYSA-N 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- STZBUZVVUVRUEG-UHFFFAOYSA-N N1=C2N(C3CCCC3)C3CCCC3C(=O)N(C)C2=CN=C1NC1CCC(O)CC1 Chemical compound N1=C2N(C3CCCC3)C3CCCC3C(=O)N(C)C2=CN=C1NC1CCC(O)CC1 STZBUZVVUVRUEG-UHFFFAOYSA-N 0.000 claims 1
- LGYXPNASGGUQDS-UHFFFAOYSA-N N1=C2N3CCCC3CC(=O)N(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 Chemical compound N1=C2N3CCCC3CC(=O)N(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 LGYXPNASGGUQDS-UHFFFAOYSA-N 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 101150117329 NTRK3 gene Proteins 0.000 claims 1
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 claims 1
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 claims 1
- 101150056950 Ntrk2 gene Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 108030005449 Polo kinases Proteins 0.000 claims 1
- 108010003506 Protein Kinase D2 Proteins 0.000 claims 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 claims 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 1
- 101150071831 RPS6KA1 gene Proteins 0.000 claims 1
- 102100024897 Ribosomal protein S6 kinase alpha-6 Human genes 0.000 claims 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 claims 1
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 claims 1
- 102100037311 Serine/threonine-protein kinase D3 Human genes 0.000 claims 1
- 102100039758 Serine/threonine-protein kinase DCLK1 Human genes 0.000 claims 1
- 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 claims 1
- 102100028948 Serine/threonine-protein kinase TAO1 Human genes 0.000 claims 1
- 101710106079 Serine/threonine-protein kinase TAO1 Proteins 0.000 claims 1
- 102100028954 Serine/threonine-protein kinase TAO3 Human genes 0.000 claims 1
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 claims 1
- 101150052413 TNK2 gene Proteins 0.000 claims 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 1
- 239000005441 aurora Substances 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical group CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- MCHVYRYQCRDWGJ-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-[(5,11-dimethyl-6-oxopyrimido[4,5-b][1,4]benzodiazepin-2-yl)amino]-4-methoxybenzamide Chemical compound COC1=CC=C(C(=O)NCCN(C)C)C=C1NC1=NC=C(N(C)C(=O)C=2C(=CC=CC=2)N2C)C2=N1 MCHVYRYQCRDWGJ-UHFFFAOYSA-N 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 0 C*(C)(C)CC(CC1)C(C2*)N1c(nc(NI)nc1*)c1N(C)C2=O Chemical compound C*(C)(C)CC(CC1)C(C2*)N1c(nc(NI)nc1*)c1N(C)C2=O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19390109P | 2009-01-06 | 2009-01-06 | |
| US61/193,901 | 2009-01-06 | ||
| PCT/US2010/000050 WO2010080712A2 (en) | 2009-01-06 | 2010-01-06 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134522A Division JP6125571B2 (ja) | 2009-01-06 | 2015-07-03 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012514601A JP2012514601A (ja) | 2012-06-28 |
| JP2012514601A5 true JP2012514601A5 (enExample) | 2013-02-28 |
| JP5908728B2 JP5908728B2 (ja) | 2016-04-26 |
Family
ID=42317095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011544638A Active JP5908728B2 (ja) | 2009-01-06 | 2010-01-06 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
| JP2015134522A Active JP6125571B2 (ja) | 2009-01-06 | 2015-07-03 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134522A Active JP6125571B2 (ja) | 2009-01-06 | 2015-07-03 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9266890B2 (enExample) |
| EP (3) | EP2379559B1 (enExample) |
| JP (2) | JP5908728B2 (enExample) |
| CA (1) | CA2748181C (enExample) |
| WO (1) | WO2010080712A2 (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| EP2379559B1 (en) * | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| TWI711610B (zh) | 2009-09-04 | 2020-12-01 | 美商百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
| WO2011143657A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| MX2012014158A (es) | 2010-06-04 | 2013-02-07 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2). |
| ES2653967T3 (es) | 2010-11-10 | 2018-02-09 | Genentech, Inc. | Derivados de pirazol aminopirimidina como moduladores de LRRK2 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9351974B2 (en) | 2011-11-10 | 2016-05-31 | OSI Pharmaceuticals, LLC | Substituted pteridinones for the treatment of cancer |
| WO2013134079A1 (en) * | 2012-03-05 | 2013-09-12 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| US20130259785A1 (en) * | 2012-03-30 | 2013-10-03 | Alstom Technology Ltd | Method and system for carbon dioxide removal |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| EP3255049A1 (en) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| WO2014031872A2 (en) * | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014160430A1 (en) * | 2013-03-13 | 2014-10-02 | Georgetown University | Small molecule lrrk2 and erk5 inhibitors |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| ES2892423T3 (es) * | 2013-03-15 | 2022-02-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| US9676792B2 (en) | 2013-03-15 | 2017-06-13 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| SMT201700160T1 (it) | 2013-04-25 | 2017-05-08 | Beigene Ltd | Composti eterociclici fusi come inibitori di protein chinasi |
| KR20160034379A (ko) | 2013-07-25 | 2016-03-29 | 다나-파버 캔서 인스티튜트 인크. | 전사 인자의 억제제 및 그의 용도 |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| EP3076966A2 (en) * | 2013-12-02 | 2016-10-12 | BerGenBio AS | Use of kinase inhibitors |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| KR20160111036A (ko) * | 2014-01-31 | 2016-09-23 | 다나-파버 캔서 인스티튜트 인크. | 디아제판 유도체 및 그의 용도 |
| US10793571B2 (en) * | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| US20170008888A1 (en) * | 2014-02-26 | 2017-01-12 | Kyorin Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| CA2940472A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| GB201411581D0 (en) * | 2014-06-30 | 2014-08-13 | Inst Europ Di Oncologia S R L | Compounds inhibiting the enzyme monopolar spindle 1 kinase, pharmaceutical compositions and uses thereof |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| US10004751B2 (en) | 2014-07-10 | 2018-06-26 | The J. David Gladstone Institutes | Compositions and methods for treating Dengue virus infection |
| EP3177147A4 (en) | 2014-08-08 | 2018-01-24 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| RU2017104897A (ru) * | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EA033325B1 (ru) | 2014-10-27 | 2019-09-30 | Тэнша Терапеутикс, Инк. | Ингибиторы бромодомена |
| EP3223821A1 (de) | 2014-11-25 | 2017-10-04 | Bayer Pharma Aktiengesellschaft | Substituierte pyridobenzodiazepinon-derivate und ihre verwendung |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| CA2981844A1 (en) | 2015-04-17 | 2016-10-20 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN108472300A (zh) | 2015-09-11 | 2018-08-31 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| KR20180051576A (ko) | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도 |
| EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| JP6754772B2 (ja) * | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| PE20181298A1 (es) | 2015-11-25 | 2018-08-07 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| CN107151250B (zh) * | 2016-03-04 | 2020-03-27 | 安徽省新星药物开发有限责任公司 | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 |
| CN109311901A (zh) * | 2016-04-07 | 2019-02-05 | 达纳-法伯癌症研究所有限公司 | 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| CN110049976A (zh) | 2016-07-21 | 2019-07-23 | 比奥根Ma公司 | 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物 |
| WO2018022802A1 (en) * | 2016-07-26 | 2018-02-01 | University Of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| MA46285A (fr) | 2016-09-19 | 2019-07-31 | Mei Pharma Inc | Polythérapie |
| AU2017346845B2 (en) * | 2016-10-18 | 2021-12-02 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| JP6728503B2 (ja) * | 2017-02-24 | 2020-07-22 | テグ−キョンプク メディカル イノベーション ファウンデーション | 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CA3087716A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| AU2019225806A1 (en) * | 2018-02-20 | 2020-07-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN109999763A (zh) * | 2019-03-20 | 2019-07-12 | 广西民族大学 | 一种去除糖浆中钙镁离子的方法 |
| WO2020219606A1 (en) * | 2019-04-22 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of erk5 inhibitors for treating gliomas in pediatric subjects |
| EP3965803B1 (en) * | 2019-05-10 | 2025-08-20 | Dana-Farber Cancer Institute, Inc. | Small-molecule focal adhesion kinase (fak) inhibitors |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021024141A1 (en) * | 2019-08-08 | 2021-02-11 | Xiaoxiang Li | Prevention or treatment of diseases and disorders associated with tissue damage |
| AU2020356484A1 (en) * | 2019-09-27 | 2022-03-17 | Dana-Farber Cancer Institute, Inc. | ERK5 degraders as therapeutics in cancer and inflammatory diseases |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR102498531B1 (ko) * | 2020-06-29 | 2023-02-13 | 한국과학기술연구원 | 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체 |
| WO2022036310A2 (en) * | 2020-08-14 | 2022-02-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ack1/tnk1 tyrosine kinase |
| WO2022078350A1 (en) * | 2020-10-14 | 2022-04-21 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| WO2022145989A1 (ko) * | 2020-12-31 | 2022-07-07 | (주) 업테라 | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| CN114478539B (zh) * | 2022-02-09 | 2024-02-02 | 中国人民解放军海军军医大学 | 一种新型dclk1抑制剂及其制备方法和应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| CN116173040B (zh) * | 2022-08-23 | 2025-05-23 | 杭州天玑济世生物科技有限公司 | Xmd17109作为arih1激动剂的用途 |
| CN116375713B (zh) * | 2023-03-07 | 2024-11-19 | 中国人民解放军海军军医大学 | 一种dclk1蛋白降解靶向嵌合体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2310039T3 (es) * | 1998-05-26 | 2008-12-16 | Warner-Lambert Company Llc | Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular. |
| KR100983462B1 (ko) * | 2003-02-26 | 2010-09-27 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 디하이드로프테리디논, 이의 제조방법 및 약제로서의 이의 용도 |
| DE102005061655A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Diazepinone |
| DE602007008837D1 (de) | 2006-02-14 | 2010-10-14 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| JP5087640B2 (ja) * | 2007-03-22 | 2012-12-05 | 武田薬品工業株式会社 | Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン |
| WO2009067547A1 (en) * | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| EP2379559B1 (en) * | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
-
2010
- 2010-01-06 EP EP10729389.6A patent/EP2379559B1/en active Active
- 2010-01-06 CA CA2748181A patent/CA2748181C/en active Active
- 2010-01-06 EP EP17178398.8A patent/EP3255047B1/en active Active
- 2010-01-06 EP EP21152496.2A patent/EP3828185B1/en active Active
- 2010-01-06 JP JP2011544638A patent/JP5908728B2/ja active Active
- 2010-01-06 WO PCT/US2010/000050 patent/WO2010080712A2/en not_active Ceased
- 2010-01-06 US US13/143,505 patent/US9266890B2/en active Active
-
2015
- 2015-07-03 JP JP2015134522A patent/JP6125571B2/ja active Active
-
2016
- 2016-01-13 US US14/994,213 patent/US9464091B2/en active Active
- 2016-08-08 US US15/231,209 patent/US9701683B2/en active Active
-
2017
- 2017-05-25 US US15/605,515 patent/US10081639B2/en active Active
-
2018
- 2018-08-22 US US16/108,725 patent/US10570154B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012514601A5 (enExample) | ||
| US20230364086A1 (en) | Combination therapies with ehmt2 inhibitors | |
| HRP20200624T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka | |
| JP7624985B2 (ja) | Ｐｒｍｔ５阻害剤の組合せ医薬 | |
| ES2572527T3 (es) | Inhibidores de PDE10 de pirimidina | |
| CN102281875B (zh) | 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法 | |
| ES2326307T3 (es) | Combinacion de un inhibidor del receptor abl, receptor pdgf y/o receptor de kit de la tirosina quinasa con un compuesto organico capaz de unirse a la glicoproteina acida-alfa1. | |
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| RU2502737C2 (ru) | Производные имидазопиридина или имидазопиримидина в качестве ингибиторов фосфодиэстеразы 10а | |
| ZA202001390B (en) | Crystalline forms | |
| ES2714718T3 (es) | Compuestos y composiciones como inhibidores de MEK | |
| KR20240167633A (ko) | 종양 치료용 약학 조성물 | |
| CN106243088B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| TW201032806A (en) | Hsp90 inhibitor combinations | |
| RU2007137983A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| NO20063758L (no) | Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer | |
| AU2014372166A1 (en) | Pharmaceutical combinations | |
| JP2013542963A5 (enExample) | ||
| NZ610018A (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| EA200901505A1 (ru) | 3,6-дизамещенные имидазо[1,2-b]пиридазины и 3,5-дизамещенные пиразоло[1,5-a]пиримидины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| TW200930374A (en) | Pyrrolo[3,2-d]pyrimidine compounds and their use as PI3 kinase and mTOR kinase inhibitors | |
| US20150164910A1 (en) | Antiviral compounds and methods of use | |
| CA2850707C (en) | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome | |
| TW201240665A (en) | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |